MarketPeel
Insider Trading Intelligence
Pricing
…
IH

Ivan Hyep

BCAX
CHIEF FINANCIAL OFFICER · BICARA THERAPEUTICS INC. · CIK 0002034668
FILING MIX · LIFETIME36%/64%
BUYS
15
SELLS
27
TOTAL VALUE
$2.50M
COMPANIES
1
ACTIVE SINCE
Oct 2025
HOLDINGS NOW
145,355
AVG SELL PX
$18.88
TRADE KIND
SHOWING 42 / 42
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
12 backtested trades · 8 horizons · 30 pending
Forward-return performance of every backtestable P/S trade by Ivan Hyep, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d12+41.67%+0.28%-0.22%+0.50%+1.53%—
14d12+58.33%-3.04%+0.26%-3.30%-4.80%—
30d12+66.67%-4.48%+0.79%-4.62%-11.77%—
60d12+25.00%+2.92%+2.40%-0.23%-1.15%—
90d12(1 pending)+54.55%+2.52%+3.27%-3.79%-12.83%—
180d12(5 pending)+0.00%+16.40%+2.32%+14.35%+17.85%—
1y12(12 pending)——————
2y12(12 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
BCAX · 145,355 shares · as of May 21, 2026
040,90081,800122,699163,5992026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2025
2026
2026
FLOW · 15 buys / 27 sellsCOVERAGE · 3 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
9,200$20.42$187.9K145,355May 21, 2026May 26, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
9,200——70,584May 21, 2026May 26, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
9,200$3.79$34.9K154,555May 21, 2026May 26, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
9,200$23.00$211.6K145,355Apr 21, 2026Apr 22, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
9,200——39,744Apr 21, 2026Apr 22, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
9,200$3.79$34.9K154,555Apr 21, 2026Apr 22, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
9,200$18.52$170.3K145,355Mar 23, 2026Mar 24, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
9,200——48,944Mar 23, 2026Mar 24, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
9,200$3.79$34.9K154,555Mar 23, 2026Mar 24, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
2,963——79,784Mar 4, 2026Mar 5, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
2,963$3.79$11.2K148,318Mar 4, 2026Mar 5, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
2,963$18.25$54.1K145,355Mar 4, 2026Mar 5, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
13,555$18.22$246.9K145,355Mar 3, 2026Mar 5, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
6,237$3.79$23.6K158,910Mar 3, 2026Mar 5, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
7,318——58,144Mar 3, 2026Mar 5, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
7,318$3.79$27.7K152,673Mar 3, 2026Mar 5, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
6,237——82,747Mar 3, 2026Mar 5, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
125,000——125,000Feb 2, 2026Feb 4, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
1,882$3.79$7.1K147,237Jan 22, 2026Jan 26, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
1,882$18.15$34.2K145,355Jan 22, 2026Jan 26, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
1,882——65,462Jan 22, 2026Jan 26, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
9,200——88,984Dec 22, 2025Dec 23, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
9,200$18.31$168.5K145,355Dec 22, 2025Dec 23, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
9,200$3.79$34.9K154,555Dec 22, 2025Dec 23, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
17,795$3.79$67.4K163,150Nov 24, 2025Nov 25, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
17,795$18.55$330.1K145,355Nov 24, 2025Nov 25, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
17,795——98,184Nov 24, 2025Nov 25, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
605$18.15$11.0K145,355Nov 21, 2025Nov 25, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
605——115,979Nov 21, 2025Nov 25, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
605$3.79$2.3K145,960Nov 21, 2025Nov 25, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
6,415——116,584Oct 9, 2025Oct 10, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
6,415$18.23$116.9K145,355Oct 9, 2025Oct 10, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
6,415$3.79$24.3K151,770Oct 9, 2025Oct 10, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
5,627$3.79$21.3K150,982Oct 8, 2025Oct 8, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
5,627——122,999Oct 8, 2025Oct 8, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
5,627$18.21$102.5K145,355Oct 8, 2025Oct 8, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
18,244$3.79$69.1K163,599Oct 7, 2025Oct 8, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
18,244$18.22$332.4K145,355Oct 7, 2025Oct 8, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
18,244——128,626Oct 7, 2025Oct 8, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
6,514$18.17$118.4K145,355Oct 6, 2025Oct 8, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Financial Officer
6,514——146,870Oct 6, 2025Oct 8, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Financial Officer
6,514$3.79$24.7K151,869Oct 6, 2025Oct 8, 2025 ↗View →
Other insiders · BCAX
Loading peer insiders…
About this filer
CIK 0002034668
ROLE
Chief Financial Officer
PRIMARY
BCAX
COMPANIES
1
ACTIVE SINCE
Oct 2025
MARKETPEEL · /INSIDER/0002034668DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback